awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26775621-259A336C-7ED2-461C-AF92-C641686541C5
Q26775621-259A336C-7ED2-461C-AF92-C641686541C5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26775621-259A336C-7ED2-461C-AF92-C641686541C5
National consensus in China on diagnosis and treatment of patients with advanced breast cancer
P2860
Q26775621-259A336C-7ED2-461C-AF92-C641686541C5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26775621-259A336C-7ED2-461C-AF92-C641686541C5
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
93e631b2332c8206358531f37627696fc57fe002
P2860
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.